Clinical assays for quantitation of insulin-like-growth-factor-1 (IGF1)

The clinical utility of mass spectrometry based protein assays

“…IGF2 is thought to have more of a role during gestation and in pancreatic β-cell proliferation and is commonly assayed to diagnose non-islet cell tumor hypoglycemia [58]. The major hurdle for analysis of IGF1 and IGF2 is avoiding interference from the strong interaction these hormones have with IGF binding proteins (IGFPB) [59]. Comparisons of existing IGF1 immunoassays found significant differences in accuracy, presumably due to differential interference from IGFBPs [60].…”

Introduction for the Special Issue of METHODS on Detection and quantification of proteins in clinical samples by mass spectrometry

“…The following four articles of this special issue discuss different quantitative proteomics methods pertinent to cardiometabolic and endocrine diseases [8][9][10][11]. Gauthier et al [8] describe and apply to patient cohorts a mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) for the quantification of plasma PCSK9 and its variants, a key protein in the regulation of blood cholesterol levels and promising therapeutic target.…”

“…Trenchevska et al [10] describe a multiplexed MSIA top-down assay for the serum quantification of apolipoproteins C-I, C-II, and C-III and their proteoforms, which are important players in triglyceride metabolism and cardiometabolic risk. Finally, the last paper of this issue, by Ketha and Singh [11], is a review article discussing the various mass spectrometric methods that have been developed for the quantification of insulin-like growth factor 1 (IGF1), a peptide hormone that mediates the effects of growth hormone and thus plays an important endocrine role.…”

Annual banned‐substance review: analytical approaches in human sports drug testing

“…- [131,132,136,[138][139][140][141][142]144,[146][147][148][149] - [24,[125][126][127][128][129][130][132][133][134][135]137,143,145] S3 Beta-2-Agonists - [159][160][161][162][163] - [24,[150][151][152][153][154][155][156][157][158] S4 Hormone and metabolic modulators 1 Aromatase inhibitors [164] - [164] [ 24,165] 2 Selective estrogen receptor modulators (SERMs) - [167,169,170] - [24,…”